PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook

BackgroundProstate specific membrane antigen (PSMA) PET imaging has recently gained attention in glioblastoma (GBM) patients as a potential theranostic target for PSMA radioligand therapy. However, PSMA PET has not yet been established in a murine GBM model. Our goal was to investigate the potential...

Full description

Bibliographic Details
Main Authors: Maximilian A. Kirchner, Adrien Holzgreve, Matthias Brendel, Michael Orth, Viktoria C. Ruf, Katja Steiger, Dennis Pötter, Lukas Gold, Marcus Unterrainer, Lena M. Mittlmeier, Enio Barci, Roland E. Kälin, Rainer Glass, Simon Lindner, Lena Kaiser, Jessica Maas, Louisa von Baumgarten, Harun Ilhan, Claus Belka, Johannes Notni, Peter Bartenstein, Kirsten Lauber, Nathalie L. Albert
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Oncology
Subjects:
Prostate specific membrane antigen (PSMA)
18F-PSMA-1007 PET
glioblastoma
GL261
preclinical
mouse
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.774017/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.774017/full

Similar Items